STANDARDISATION AND PHARMACOLOGICAL EVALUATION OF BRACLITAB SUSPENSION IN THE CHICK USING ANXIETY DEPRESSION MODEL
Authors: Varsha G , SAI BALAJI O, FOUZIYA M, DINESH KUMAR, AUSAAF AHMED SIDDIQI, SUMITHRA M*

ABSTRACT
Introduction: Depressive disorder is a prevalent psychiatric disorder, which affects 3.5 % of the world’s population. The presently using drugs can impose a variety of side effects including cardiac toxicity, hypokinesia, sexual dysfunction, body weight gain, and sleep disorder. During the last decade, there is a growing interest in the therapeutic effects of natural products on mental disorders. Tabernaemontana divaritica, Clitoria ternatea, and Centella asiatica were investigated for antidepressant activity. Methods: Braclitab suspension was prepared using the hydroalcoholic extract of Tabernaemontana divaritica, Clitoria ternatea, and Centella asiatica and then subjected to standardization followed by FTIR analysis to confirm herb-herb interaction. The antidepressant activity was studied through stress induction in the chick model and hydroalcoholic extract of was subjected to anti-depression activity in the chick model using stress vocalization and glutathione reductase activity using the chick model. Results: It has been observed from our study that vocalization study is reduced with the drug administration and recent studies suggest that oxidative stress pathways may contribute to the pathogenesis of depression by interacting with the monoamine reuptake process. It was reported that individuals who suffer from depression displayed lower antioxidant potentials and reduced brain GSH levels by glutathione reductase assay. Conclusion: However further study is needed to understand the mechanism of action and to identify the active component responsible for the antidepressant-like activity. Keywords: Antidepressant Activity, GSH, Glutathione reductase, stress vocalization
Publication date: 01/11/2023
    https://ijbpas.com/pdf/2023/November/MS_IJBPAS_2023_7476.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.11.7476